Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Benchmark raised their target price on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Trading Up 0.9 %

Shares of HUMA opened at $3.40 on Wednesday. The stock’s fifty day simple moving average is $4.36 and its 200 day simple moving average is $4.96. Humacyte has a twelve month low of $2.81 and a twelve month high of $9.97. The firm has a market capitalization of $427.92 million, a P/E ratio of -2.54 and a beta of 1.30.

Institutional Trading of Humacyte

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Humacyte by 10.8% during the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after acquiring an additional 543,995 shares during the last quarter. State Street Corp raised its stake in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Woodline Partners LP lifted its position in shares of Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the last quarter. Geode Capital Management LLC grew its stake in Humacyte by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock worth $10,785,000 after purchasing an additional 94,915 shares in the last quarter. Finally, CenterBook Partners LP bought a new stake in Humacyte in the fourth quarter valued at about $6,463,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.